Anaconda Biomed has raised $56m to advance the clinical development of its mechanical thrombectomy catheter portfolio and complete the pivotal investigational device exemption (IDE) study for its ANA funnel catheter.
The Spain-headquartered company’s financing round was led by Omega Funds and was joined by new investor FOCO, a co-investment fund established by the Spanish government and managed by Spanish Development Finance Company (COFIDES). Existing investors including Asabys, Ysios Capital, and CDTI also participated.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Anaconda highlighted that a key part of the latest financing tranche will go towards the completion of the ATHENA pivotal IDE study (NCT06370182) evaluating its ANA funnel catheter.
ANA is designed to improve clot capture, reduce embolic complications and maximise brain reperfusion. In combining aspiration power with flow-arrest and flow-reversal, the platform is being developed to address clot retrieval, fragmentation and downstream embolisation, taking on thrombectomy’s “most persistent challenges”, the company stated.
Anaconda’s CEO, Trent Reutiman, said: “This latest funding round allows us to further advance our work in the acute treatment of those suffering a stroke, with the goal of reducing disability and death caused by large vessel occlusive disease.
“The support of this leading group of investors reflects the growing confidence in our technology platform, and the funds raised will ensure that the company has the required resources to complete the clinical and regulatory requirements.”
Anaconda’s overall portfolio is targeting a large and currently underpenetrated stroke intervention market. It highlighted that of the seven million deaths caused by stroke annually 65% are ischaemic strokes, 30% of these patients are treated using mechanical thrombectomy. According to the company, this translates to nearly 270,000 mechanical thrombectomy procedures performed globally in 2026, representing only a fraction of the total addressable market.
Neurovascular thrombectomy space advancements
According to GlobalData analysis, the stroke treatment market is shifting in favour of advanced aspiration technologies.
Pending its entry onto the US market, Anaconda’s ANA is likely to face especially stiff competition against established players specialising in the aspiration catheter segment, including Penumbra, which was acquired by Boston Scientific in a $14.5bn deal in January 2026.
In June, Penumbra’s Thunderbolt system, the first device to offer computer-assisted vacuum therapy (CAVT) for stroke intervention, secured US Food and Drug Administration (FDA) approval. GlobalData analysis reveals that the neuro aspiration thrombectomy market has become more competitive, with Penumbra and Imperative Care now together holding close to a 60% of the US market share.
Meanwhile, the global neurovascular thrombectomy devices market, of which Anaconda is hoping ANA will become a part of, is growing at a CAGR of 7.3% and is projected to reach a valuation of around $2.2bn in 2035, up from $1.1bn in 2025, as per GlobalData analysis.
